click contribut analyst contact
navig bridg
neutral vs growth
competit headwind alongsid tangibl manifest
drug cost contain potenti mitig increasingli
attract valuat among larger-cap expect
increas activ enthusiasm backstop
smid host catalyst set tone
year believ investor look set
preponder major clinic data drug launch polit
activ still see number opportun sector
favorit name includ celg among large-cap
gmda among mid/
biotech team host confer call et wed
contact salesperson dial-in
studi contrast saw strong run smid cap
summer kick year bang autumn regress
coupl continu large-cap stagnat left mani investor
exit year frustrat exasper generalist money flow key
ingredi sector health also never materi even follow
elect whose outcom surfac least look optim
space yet time spite record-
break level capit pour particularli new issuanc
limit actual pull-through drug cost contain initi large-
cap compani trade histor low multipl forward price-to-earnings
arguabl better-than-ev innov regulatori environ
seem new acquir
see pick leav number early-
year catalyst could help set tone year gener
think rel fewer major data readout high-profil
launch could provid opportun re-ignit interest
expect larger-cap compani creep new manag team
settl pipelin busi develop effort take shape ip
develop unfold provid greater clariti long-
term diversif strateg direct revenu sustain
potenti close gap large-cap pharma trade
forward price-to-earnings could augment increment value-ori
generalist re-visit space well like slow financ
pace draw specialist money back larger name small/smid-
cap valuat normal larg biopharma better
posit execut expect final see meaning
pickup acquisit mani predict year enabl
big winner among small/smid/mid cap help put
continu next page
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
biotech outlook report navig bridg
broader backstop recent downturn persist concern drug price polici
coupl broader market choppi perpetu volatil high-beta biotech
space like cap widespread enthusiasm
major early-year catalyst set tone year concentr key clinic
regulatori catalyst first half year like shape sentiment around specif
area innov group whole phase nash data intercept
gilead help defin feasibl bring compound line could
next multi- space even commerci unknown remain sage phase ii/iii post-partum
depress data sarepta limb girdl muscular dystrophi result like
influenc whether resurg neurolog continu stall potenti regulatori
approv karyopharm selinexor intra-cellular lumateperon jnj esketamin
among other inform fda permiss toward approv earli mix
data mani eye like potenti approv label price uptak
novartiss well fda feedback sarepta microdystrophin gene therapi
marker regulatori payer attitud toward gene therapi early-year ip
develop includ potenti mylan ipr institut biogen tecfidera
celgene-dr reddi settlement could shape percept sustain large-cap
revenu stream vs need bd among key sector catalyst investor
survey bullish sage intercept ocaliva nash studi work
celg reach favor settlement forese gilead selonsertib hit
primari endpoint tecfidera ipr institut
see high likelihood pick year gener select winner around smid-cap
biotech help stem recent downsid large-cap biotech flush
cash balanc sheet despit rise interest rate environ capit remain
rel cheap growth slow commerci franchis matur patent cliff
key product revlimid tecfidera taf inch closer highlight need diversifi
creat recip opinion talk year yet
fulli materi see uptick number biopharma deal total deal valu
vs last year activ still fell way short expect high water mark deal
valu set howev small/smid-cap valuat come
new senior manag mani large-cap biotech establish believ
well final see pickup someth believ place backstop slide
mid-cap stock sarepta loxo neurocrin immunomed view investor
survey like takeout candid saw potenti
consolid large-cap vertex still note recent lack pull-through
tesaro endocyt acquisit rest sector investor expect
alreadi appear high survey buy-sid alreadi view biggest tailwind
space make us think rise dealmak apt benefit
acquir compani closely-rel stock may broadli re-ignit enthusiasm across
report examin depth key theme drug pricing/polici innov
growth human capit individu collect could influenc
biotech sector come year note key theme mostli
one evalu throughout except human capital/manag chang
replac tax reform impact like differ come year
biotech outlook report navig bridg
discuss extens earlier increasingli bullish
valuat palat large-cap compani appear ready/wil
expect wave innov particularli across new emerg modal like
mrna gene manipul bispecif cellular therapi precis medicin
continu unab backdrop sustain favor regulatori environ
last year foster new molecular entiti nme approv sinc
weve also move neutral stanc sentiment despit market frustrat exit
survey show cheap valuat expect serv improv
investor outlook somewhat
flip side increasingli tangibl polici propos potenti polit
narr continu elect year make us neg impact
cost contain space especi true enter first year
biopharma self-pol drug price increas like challeng year-over-
could see least temporari slowdown fervent financ
environ due choppi market mix post-ipo stock perform
 ntgn though analysi suggest similar
number compani potenti need rais capit come year
import window remain open
competit weve highlight year whose potenti impact
start discuss remain import headwind particularli area like
inflamm oncolog certain neurolog space cap market share potenti
provid payer leverag control price continu believ competit
landscap need increasingli critic factor assess potenti invest
opportun space
take middl ground impact ip develop could space
year prospect reassur settlement celgen life cycl clariti
well favor ipr procedur chang also potenti setback
earn growth remain tepid among larger-cap compani analysi
suggest room miss despit low sale expect bullish
survey investor luxturna spark bearish spinraza
capit look pois mix factor influx pharma execut
provid fresh perspect also highlight matur large-cap among small
cap favor manag stabil could off-set risk valuat fragil
among stock inflat outsiz manag premium rel stage
develop
bridg look somewhat averag year come
catalyst flow drug launch shape dramat differ massiv
could substanti effect long-term fortun large/mid-cap biotech
celgen ozanimod ibd myeloma sarepta microdystrophin dmd sage
major depress disord check slate multi- potenti launch
could defin new space rewrit exist competit balanc nash drug vertex cf
tripl combo roche/ptc sma celgen luspatercept ozanimod abbvi
upadacitinib plenti top elect year drug
price rhetor like domin headlin could certainli wild ride dont
want get ahead key catalyst fall first part
year could see biotech sector trade larg part rest
year anticip forc
biotech outlook report navig bridg
name like
large-cap side
celg improv oper execut manag enhanc recent
turnaround late-stag pipelin think gener revlimid settlement
success ozanimod nda file provid key miss piec need
establish investor confid certainti revlimid tail prospect
revenu diversif help share appreci come year
share trade discount part due declin ep manag
transit see new ceo take helm earn stabil
progress pipelin filgotinib nash busi develop enabl return
growth someth believ reflect stock current valuat
mid-cap side
among neurolog compani continu remain bullish base
under-valued potenti oral drug depress disord
potenti high-efficaci safe rapid act short-cours therapi believ could
substanti chang treatment paradigm see high likelihood januari
agent posit reaffirm drug activ across indic total
see continu solid foundat exondi potenti expand
near term dmd franchis regulatori clinic progress golodirsen
casimersen addit believ street continu underappreci
impress initi express biomark clinic evid benefit
microdystrophin gene therapi program see potenti would
expect near term clariti regulatori path augment potenti strong data
emerg limb girdl program off-set potenti competit concern improv
investor confid abil drive substanti lt gene therapi revenu drive
oncolog space like see catalyst rich reignit
adcetri commerci growth indic expans trial
anticip robust launch benefit high unmet medic need overal
surviv benefit lack potenti launch headwind price concern vs unmet
need limit uptak commun set
believ investor begin better appreci jakafi sustain
fundament see addit upsid underappreci pipelin
asset progress visibl improv potenti jakafi life cycl extens effort
compani adjust capit use and/or portfolio composit
continu like see strong well-valid platform
emerg commerci footprint tibsovo/idhifa sever wholly-own
potenti blockbust asset develop pkd mtap
continu bullish bring multipl catalyst
favor risk/reward setup lead drug includ pivot readout
addit data expect data addit differenti
orally-administ kallikrein inhibitor could drive signific share appreci
pivotal-stag cord blood cell expans technolog nicord wholly-own
nam-bas platform continu view gmda emerg player stem cell
transplant space given prior data proven team clear path uniqu market
opportun advanc hematolog malign
biotech outlook report navig bridg
know like lot up down intens biotech never
seem let know alway help navig newsflow
complex weve got team broad rang expertis look forward
continu work come year
great holiday season happi invest
-- brian kennen greg biotech
biotech outlook report navig bridg
tabl content click navig
year review outlook
summari view
best idea
theme drug price polici
theme earn growth
biotech outlook report navig bridg
learn think
biotech outlook report navig bridg
eras much gain among smid-cap large-cap perform improv
expect macro environ still drag overal perform sector
macro factor rise interest rate trade uncertainti drove under-perform investor
turn less riski tradit defens sector
smid- large-cap perform converg enthusiasm also wane though small-cap still
significantli outperform ytd
price exclud acquir compani
outlook slightli bullish favor tailwind like innov regulatori permiss tax
reform
biotech outlook report navig bridg
neutral competit growth headwind alongsid tangibl manifest
biotech outlook report navig bridg
word look close came stand today sever
tailwind look less favor key headwind persist
biotech outlook report navig bridg
averageslighli bullishslightli bullishneutr headwindsneutralslightli bearishslightli bearish tailwindsslighli bullishbullishslightli price policyslightli bearishneutralslightli bearishcompetitionslightli bearishslightli bearishslightli bearishpat cliffsslightli bullishneutralneutralregulatori landscapeveri bullishveri bullishveri bullishtherapeut area emergenceveri bullishveri bullishveri bullishhuman capit -- neutralm aslightli bullishslightli bearishveri bullishearn growthslightli bearishveri bearishveri bearishfinanc environmentslightli bullishveri bullishneutralsentimentneutralslightli bearishneutraltax reformslightli bullishveri bullish- biotech outlook report navig bridg
summari view key sector headwind tailwind
earn growth -- long-term growth continu key
headwind
sector compani work grow pipelin
larger revenu base current valuat
contribut
look like may
overli discount dynam
drug price polici -- trump administr continu
aggress approach drug price increas likelihood divid
congress work togeth pass meaning reform come mid-
term see drug price higher risk sector said
alreadi account decreas abil use drug price lever growth
see draconian chang reimport central part negoti etc
unlik
competit -- import neg effect
innov
regulatori permiss one may fulli appreci
medium-term headwind sector likelihood increas
oncolog certain neurolog space greater public privat
payer empower like leverag control price
sentiment -- despit sens gener frustrat among investor
exit year sentiment base survey appear
improv somewhat larg predic prospect low
valuat though remain overhang lack actual deal
occur would like continu keep generalist
investor
sidelin could temper overal perform
innov -- core fundament driver biotech sector d-
view multipl
technolog advanc reach clinic invest
compani creation continu flow healthi pace
regulatori landscap -- regulatori trend continu look
favor fewer high-profil approv expect
believ natur approv well like
trial design surrog
endpoint mid/late-stag drug continu highlight
increasingli permiss environ benefit drug develop
pipelin need manag chang catalyz greater
necess thu see environ prime deal-
financ environ -- follow record-break year public
privat invest expect slowdown ipo market
return focu later-stag de-risk asset follow mix
ipo perform though platform compani continu reson well
overal public privat invest space remain strong
bode well continu innov fund new technolog
capit -- influx new manag member big pharma
large-cap biotech could provid fresh perspect foster improv
capit alloc portfolio diversif
though also
highlight compani matur could keep investor
sidelin
new team gain foot meanwhil mid/smid-cap
name high growth opportun may perceiv
stable/invest could risk among smaller-cap compani
whose valuat inflat manag premium
patent cliff -- see advanc key life cycl
settlement patent cliff inch closer believ increasingli
imper large-cap compani make substanti progress life cycl
pipelin develop posit side
process chang help brand drug manufactur better
defend patent portfolio time
biotech outlook report navig bridg
price
stock coverag across three analyst team span cap size numer therapeut area
year cumul sell-sid research experi across franchis
graduate-level profession degre industri expertis across scientif research drug develop clinic medicin payer price
reimburs commerci strategi market analyt busi develop financ intellectu properti regulatori
pharmaci distribut suppli chain
compon rbc comprehens healthcar research cover key core subsector
cap companytickerratingptpric brian abraham alder hold scienc nv sponsor design therapi renza gamida cell cap companytickerratingptpric kennen mackay ph abeona oncolog prime corp genet pharma biotech outlook report navig bridg
best idea
abraham op tgt share trade discount part due declin ep manag
transit see new ceo take helm earn stabil progress pipelin
filgotinib nash busi develop enabl return growth someth believ reflect
stock current valuat
celg abraham op tgt improv oper execut manag enhanc recent
turnaround late-stag pipelin think gener revlimid settlement success ozanimod nda file
provid key last miss piec need establish investor confid certainti revlimid
tail prospect revenu diversif help share appreci come year
abraham op tgt remain bullish base under-valued potenti oral drug
depress disord potenti high-efficaci safe rapid act short-cours therapi
believ could substanti chang treatment paradigm see high likelihood januari agent
posit reaffirm drug activ across indic total repres market opportun
abraham op tgt see continu solid foundat exondi potenti
expand near term dmd franchis regulatori clinic progress golodirsen casimersen
addit believ street continu underappreci impress
initi express
biomark clinic evid benefit microdystrophin gene therapi program see
potenti would expect near term clariti regulatori path augment potenti strong data
emerg limb girdl program off-set potenti competit concern improv investor confid
abil drive substanti lt gene therapi revenu drive share appreci
biotech outlook report navig bridg
best idea continu
abraham op tgt believ investor begin better appreci jakafi sustain
fundament see addit upsid underappreci pipelin asset progress visibl
improv potenti jakafi life cycl extens effort compani adjust capit use and/or
mackay op tgt like see catalyst rich reignit adcetri
commerci growth indic expans trial anticip robust launch
benefit high unmet medic need overal surviv benefit lack potenti launch headwind
price concern vs unmet need limit uptak commun set
mackay op tgt continu like see strong well-valid platform
emerg commerci footprint tibsovo/idhifa sever wholly-own potenti blockbust asset
develop pkd mtap delet tumor
abraham op tgt continu bullish bring multipl catalyst
favor risk/reward setup lead drug includ pivot readout addit data
expect data addit differenti orally-administ kallikrein inhibitor could
gmda renza op tgt pivotal-stag cord blood cell expans technolog nicord wholly-
own nam-bas platform continu view gmda emerg player stem cell transplant space
given prior data proven team clear path uniqu market opportun advanc hematolog
biotech outlook report navig bridg
reevalu top theme look
biotech outlook report navig bridg
investor survey indic slightli increas optim go
particularli generalist expect biotech sector larg
outperform
investor maintain
launch clinic data catalyst lesser degre
favor regulatori environ earn growth key
posit driver agre bullish
area except earn growth see larger revenu
base difficult
grow scrutin price
environ challeng earn growth
robust occur could help stimul generalist fund
re-ent sector caus market upsid
generalist money slowli return sector
sell-off eras sector gain activ like
necessari stimul growth polit pressur
drug price increas stymi sourc earn revenu
growth compani across sector inde key concern
cite investor go
beyond drug price concern competit primari concern
among investor unpreced contract free drug
agreement made headlin specif cgrp
take despit sens gener frustrat among investor exit year sentiment base survey appear
improv somewhat larg predic prospect low valuat though remain overhang lack actual deal
occur would like continu keep generalist investor sidelin could temper overal perform
survey investor gaug sentiment go
biotech outlook report navig bridg
long-onli demograph biotech outlook report navig bridg
investor lean toward see sector under-valued head rel
see overvalu
believ reflect mix sentiment space lean posit
greater portion survey
investor view space
under-valued compar
last check octob
valuedundervaluedinvestor current view biotech valuedundervaluedinvestor current view biotech valuationsgeneralistsspecialist investor larg expect biotech outperform broader market
consequ investor expect rel perform remain optimist
biotech outlook report navig bridg
investor optimist
sector rel perform
octob
 in-lin expect rel biotech in-lin expect rel biotech performancegeneralistsspecialist major investor plan maintain posit
investor plan decreas exposur sector
biotech outlook report navig bridg
gener line
investor plan increas
exposur compar
given hedg fund posit
biotech near all-time-high
see recalibr
equal weight posit
posit posit biotech outlook report navig bridg
littl consensu among favorit large-cap though investor tend favor
celg
far prefer large-cap among generalist indic import aducanumab
readout factor ip event could affect sector also favor
celg favor among specialist
least prefer large-cap among investor survey
favor large-cap favor large-cap biotechsspecialistsgeneralist biotech outlook report navig bridg
investor look toward prospect drive perform drug price
concern remain overhang
investor seem optimist prospect new therapeut area emerg drive
sector growth
drug price polici remain front-of-mind concern like due one area bipartisan
support head split congress competit surfac anoth headwind year outlook
cgrp made headlin unconvent competit approach
sentiment one biggest
headwind sector
view space like
reflect percept
generalist sentiment still
biotech outlook report navig bridg
fda commission scott gottlieb continu advanc project
believ favor overal landscap drug approv instanc
recent announc use real-world data rwd could
implic medic use off-label potenti make easier add
indic broaden clinic use addit agenc
pursu robust rapid guidanc develop aid clarifi new drug
develop pathway eas use/access
increas flexibl around label design includ broad indic
agnost label basket approach increasingli favor
number approv nme orphan drug design approv
percentag applic approv increas year-over-year among
product approv year sever cgrp treatment migrain
prophylaxi aimovig ajovi emgal well spark luxturna first
vivo gene therapi approv gild biktarvi rapidli grow hiv
treatment gene therapi particular interest track
expect
new
modal potenti benefit compani like
increasingli favor regulatori pathway
fda place increas emphasi speed-to-market perhap best
demonstr sgen approv adcetri via rtor real-tim
oncolog review though read gener competit
well see net posit sector new therapi could
potenti face fewer barrier order reach market
discuss detail competit section increas number
product approv quickli lead increas competit though
fda directli regul price drug commission gottlieb
believ best way control drug price market
encourag competit innov allow drug come
market fda initi set sight eas pathway approv
gener complex gener biosimilar lead us believ
gener space disproportion affect polici though
increas competit eventu affect brand drug line
scrutini orphan drug design remain especi wake
grow number blockbust orphan drug first approv narrow
expand broader popul rituximab humira
revlimid though concern come fruition last year fact
record number orphan drug approv recent attent
fda design process exampl allow applic proceed
miss inform popul size may add increas
pressur compani seek design go forward
effort increas transpar fda publish shame list
firm creat obstacl gener competitor though fda
dictat price increas attent area could ultim provid easier
path gener entri road across indic
take regulatori trend continu look favor fewer high-profil approv expect believ natur
approv well like continu amen toward novel trial design surrog endpoint mid/late-stag drug continu highlight
increasingli permiss environ benefit drug develop reduc risk
uptick nme bla approv led highest total sinc
biotech outlook report navig bridg
compar last year
nme approv sinc
approv rate top
follow rel low
approvalsnm approv nme new bla approv biotech outlook report navig bridg
acceler approv steadi compar previou year
fda histor select
acceler approv
trend continu year
acceler approv grant
vstm
acceler approv grant
indic poor prognosi
treatment rare diseas
aa year cancer
indic other ntm
infect fabri fxa-i revers
companytickerdruggener nameindicationapprov datereview prioriti orphan statusapprox popul phasedatatri designmerckmrkkeytrudapembrolizumabmetastat orr pr patient random dose test johnson line mo pt random open-label studi dose test intercepticptocalivaobetichol line iiialp reduct pt placebo-control randomizedsarepta srptexondi exon placebo mep higher pt random placebo control pt open-label single-armclovisclvsrubracarucaparibr/r brca mut ovarian recist brca mut pt single-arm open labelastrazeneca aznimfinzidurvalumabadvanc bladder yrphase orr cr pt single-arm open-labelcelgenecelgidhifaenasidenibr/r mutat yrphase orr cr mo median os pt open-labelportolaptlaandexxacoagul factor xarevers factor xa inhibitor-rel yrphase decreas anti-factor xa activ placebo control studi amikacinnon-tubercul mycobacterium yrphase sputum convers refractori pt placebo-control approv grantedacceler approv biotech outlook report navig bridg
number breakthrough therapi design grant line
breakthrough therapi design per year approv
trend upward sinc first full year program
decemb
all-tim high breakthrough drug
approv decreas
approv breakthrough design grantedbreakthrough design request breakthrough drug approv though number orphan drug design decreas orphan drug approv
all-tim high
biotech outlook report navig bridg
number orphan drug design grant orphan drug
fda made prioriti
address backlog orphan
drug design request
grant orphan drug
design year
record
reduc number orphan drug
design grant
impli fda
larg work
even lower number
number orphan drug
approv in-lin
scott gottlieb state goal
includ uniqu indic separ approv
drug design grantedorphan drug approv major regulatori event highlight outlook favor outcom
biotech outlook report navig bridg
favor outcomeunfavor outcomecompanydrugeventtimingnot label featur regulatori event monitorclvsrubracachmp opinion treatment ovarian cancer safeti languag updat rubraca label relat warn precaut sectionregndupilumabsubmiss regulatori file adult sever nda submiss relapsed/refractori ind applic mtap pathway develop ema approv submiss dec earli meet discuss registr earli meet review phase ii nhl studi discuss registr path fl provid updat decis soliri gmgearli chmp opinion label expans meet discuss approv class hepatotox warn lack thereofdvaxheplisav-bacip mainten ovarian decis scenario label updat includ chang black box warn sever child pugh b/c patient black box warn sever mid pbc patientssrptexondi bsufa label updat relat dose whether dose allow mo load phasecelgozanimodnda file first dose monitor requir includ class cardiac toxicityincybaricitinibnda re-submiss potenti approv fda file mani remain regulatori event halftim report favor outcom
biotech outlook report navig bridg
favor outcomeunfavor outcomecompanydrugeventtimingnot label featur regulatori event monitorpbyinerlynx neratinib chmp opinion extenet re-examin last week label all-com vs patient feedback next step ivosidenib aug pdufa data rel/ref aml treatment in-lin idhifa label minimum eu approv eu aggress us regulatori path file eu requir addit studi usonceluxturnapotenti chmp opinion retin pdufa date dose sbla regulatori approv use infant year pdufa date vrtxorkambipotenti approv children pdufa date regndupixentoct pdufa date sever label all-com vs eosinophil-high patient regncemiplimaboct pdufa brexanolon chmp opinion exondi fda meet discuss potenti acceler fda feedback ind sickl cell fda potenti psc path therapiespotenti expedit peanut allergi age rang ped vs ped adult clvsrubraca rucaparib potenti chmp opinion recurr mainten complet fda dystrophin collection/analysi discuss approv romosozumab potenti chmp opinion ae commentari upcom notabl regulatori event
biotech outlook report navig bridg
companydrugeventtimingnot label features/regulatori event monitorkptiselinexorsubmit condit approv penta-refractori hccjanuari drl ipr md mou patentsfebruari pnhfebruari date acut gvhdfebruari ad adolesc sbla march lotu ipr mm mou patentsmarch brexanolon pdufa target date zulresso ppdmarch restrict locat black box warningaldr eptinezumabbla file rrm ind infantil batten diseas hear on-going anda litigationaprilkptiselinexorpdufa date selinexor penta-refractori mmapril cv risk reduct sbla april hyperlipidemia sbla april diabet retinopathi sbla may fact discoveri on-going anda litigationmay submiss submiss peanut allergi file us eu jp decis decis inclus mainten treatment ovarian cancer eu file pomp decis sbla pre-fil approv biotech outlook report navig bridg
drug price polici
draconian chang drug price may still fear occur
remain unlik even light increas increment reform
possibl congress govern
posit
intervent unlik central bodi coordin
capabl develop meaning price measur
biopharma industri modestli improv abil
commun valu organ messag price strategi
intent vs player pbm though on-going
improv would still benefici sector
new value-bas initi novel strategi author
gener could continu improv reimburs paradigm
new market entrant offer accept compromis
improv comprehens awar price
reimburs pressur affect sector market
insul market continu stay protect larger
competit market remain expos payer target class
sever therapeut option cost contain opportun
continu see orphan drug certain oncolog class
split elect outcom initi seem ideal given potenti challeng split
congress would pass meaning reform polici expert weve spoken see
increas likelihood drug price area could see cooper
recent held unconstitut percept polit risk
space could amplifi though final legal decis like mani year away
unlik result major chang view
trump administr aggress pursuit
drive price chang
includ emerg involv fda price debat public scrutini
alon influenc frequenc magnitud compani will
state drug price transpar initi continu ramp well increas
potenti congression hear especi democratic-control congress
begin presidenti campaign like renew nation attent
drug price especi healthcar key mid-term elect issu
complex new entrant car-t gene therapi like add fuel
debat therapeut spend despit focu valu new price deliveri
model may take time establish
competit market like particularli expos payer target therapeut
area sever option cost contain opportun formulari placement
valu outcomes-bas price reauthor tool payer
dispos like impact specialti area biotech play
tradit insul market like ms hiv begin see somewhat
increas formulari manag though see rel low-risk attempt deriv
plan cost save therapeut area strategi unlik stray
far clinic guidelin
take trump administr continu aggress approach drug price increas likelihood divid congress work
togeth pass meaning reform come mid-term see drug price higher risk sector said alreadi account
decreas abil use drug price lever growth see draconian chang reimport central part negoti etc unlik
biotech outlook report navig bridg
surprisingli recent price trend skew neg commerci government payer
continu exert influenc biopharma neutral abil util price drive sale
expect continu scrutini commerci payer govern side aisl
galvan around drug price spend exert influenc manufactur
expect price-driven growth remain in-check see signal relief price pressur return
old way price increas legaci drug prop biotech revenu growth
pattern price hike still seen stakehold earli stage digest
dialogu quantif valu product price believ manufactur could even less empow
maintain establish new leverag payer suppli chain patient despit effort underway
construct approach payment reimburs
histor averag sales/trx monitor biotech product show shift price growth sale
driver despit price offset softer volum earli trend away price power expect sustain
changesal growthvolum growthimpli price growth biotech outlook report navig bridg
trump administr highli activ implement chang feder drug program
still rel low impact term compani bottom line potenti cumul
effect chang drug-mak worri
includ recently-announc polici tie part reimburs ex-u price increas
flexibl manag protect class part
polit narr also decis shift away pbm payer toward drug manufactur
executivecongressionalblueprint strategyactionactioninitiativepart dpart bmedicaidprivatex increas oversightxxxban pharmaci gag clausesxxxxremind part patient toolsxxxbiosimilar action planxxxxxincreas gener approvalsxxxxxrem abus shame listxxxxxguid citizen petit anti-trust reviewxxxxximport sole sourc drugsxxxxxorphan drug design clarificationsxxxxxindication-bas managementxxstep edit medicar part bxxconsolid part d/b programsxxxintern price payment modelxxomb rule chang anti-kickback statutexxincreas formulari flexibilti protect classesxxcm dashboard increas price transparencyxxxxxend price reset line extensionsxx disclosur list price dtc advertisingxxxxxrep ipabxxxmedicar part donut hole changesxmedicarelow out-of-pocket costscreat incent lower list pricesotherincreas competitionstrengthen negoti state initi around price regul transpar remain worth watch
biotech outlook report navig bridg
stateinitiatived manufactur prescript drug give notif day advanc price increas wac increas exceed two-year period quarterli report justifi wac increas list wac increas period five cost new drug exce medicar part specialti threshold requir manufactur notifi state least three day launch submit report detail price market plan day later assembl manufactur provid subsidi copay pocket expens therapeut equival provid patient insur louisianaact must document report wac drug market state dept must compil list essenti diabet treatment identifi drug price increas exceed cpi cpi medic indic identifi manufactur requir submit report detail factor wac increas provid inform cost product market advertis profit pbm must submit list prescript drug sale rep identifi sale rep must provid report detail yearli compens drug sampl provid new drug expenditur exceed annual growth limit ny dept may identifi drug supplement medicaid rebat request manufactur request target rebat target rebat provid manufactur must report cost manufactur distribut market advertis price rebat offer compil list drug state spend signific health care dollar wac increas year year manufactur must justifi attorney gener reason price wholesal import program import predetermin high-cost pharmaceut canadawashingtonhb sb legislationrequir manufactur submit specifi data drug increas price one year past three year also allow privat organ collect verifi report price data massachusettshb sb hb legislationmanufactur would need justifi price increas year year offic attorney gener also requir manufactur top sell drug state provid detail report manufactur cost market cost cost privat public purchas illinoi sb on-going legislationmanufactur requir notifi public privat purchas least day price increas requir manufactur specifi price new prescript drug day commerci avail allow depart public health publish inform internet pennsylvaniahb sb on-going legislationestablish pharmaceut transpar commiss would determin whether retail price drug reason pbm insur would need pay premium commiss determin reason cost also would requir manufactur sell drug state provid annual report cost market consum rebat vermontsen result on-going lawsuit investig government initi could broad read-through
biotech outlook report navig bridg
eventdescript impactsen gao investig orphan drug price last year senat hatch grassley cotton submit letter govern account offic gao concern pharmaceut compani may take advantag orphan drug act oda specif cite multipl design allow orphan drug act potenti problem gao accept request expect begin investig near end updat investig releas investig examin drug expand beyond orphan indic whether oda actual incentiv develop drug orphan indic provid recommend regulatori legisl chang preserv intent law given increas scrutini surround orphan drug believ investig worth follow given potenti neg ramif compani current util oda ir investig charit donat patient assist chariti ir recent step investig practic drug manufactur donat patient assist chariti donat chariti help patient afford expens co-pay necessari medic may violat anti-kickback law sinc drug compani directli benefit donat use purchas drug made manufactur agre pay settl lawsuit doj violat feder anti-kickback statut similar on-going whistleblow lawsuit celgen face alleg money donat chariti intent steer contribut toward drug lead charg improv drug price confirm secretari hh januari vocal propon trump administr american patient first blueprint lower prescript drug price element blueprint includ propos give feder govern power negoti drug price move medicar part drug part remov barrier gener drug competit requir drug price disclos tv commerci recent senat hear presid blueprint field question numer senat express frustrat lack immedi impact drug price perceiv limit negoti power outlin plan inabl administr offer discret timelin initi begin benefit american drug discount program larg cap limit exposur though continu monitor movement percept public payer front pricing/reimburs overal potenti headlin risk believ chang purchas paramet would meaning read-though time legal challeng drug price transpar law could yield posit result
biotech outlook report navig bridg
note biopharma initi number lawsuit challeng drug price transpar law
 court appeal rule maryland law prohibit unreason price increas
unconstitut violat commerc claus disallow state regul commerc
believ rule posit implic drug-mak face type transpar law
state like ca sb phrma argu also violat commerc claus
ca law slightli differ maryland relat disclosur rather action
price increas believ argument relat violat commerc caus like
phrma also argu sb unconstitut violat due process claus well first
eventdescript impactphrma lawsuit california ssenat pharmaceut research manufactur america phrma file lawsuit california challeng senat law target drug manufactur would requir justif drug price hike pass complaint state sb would improperli regul price drug outsid california jurisdict compel drug manufactur commun california drug price messag maryland drug-price-goug law rule unconstitut maryland first state grant state attorney gener author take action drug manufactur increas price pre-set limit court appeal rule law unconsitut directli regul transact take place outsid maryland rule may import implic similar case phrma lawsuit california sb wane collect annual list price increas prior year remain base case though
rate declin slow price growth lose influenc concept disciplin
price becom broadly-accept dynam
biotech outlook report navig bridg
note analysi includ product celg relev competit
biotech outlook report navig bridg
mani resourc strategi
extend life cycl key product key detail remain scant
mani key patent expiri think specif may
emerg come year potenti settlement celg
revlimid combo/formul strategi inci jakafi
dispos
number favor procedur chang ipr process
new director patent offic posit patent
fda implement number initi improv
speed biosimilar gener reach market uptak
rel slow
mani biotech yet elucid exact pathway
plan manag key life-cycle patent cliff limit progress
toward aim either product extens diversif
time act continu shorten
greater regulatori anti-trust scrutini enabl faster pathway
backlog anda could continu cap longev biotech
take see advanc key life cycl manag strategi strateg transact ip lawsuit settlement
patent cliff inch closer believ increasingli imper large-cap compani make substanti progress life cycl pipelin
develop posit side ipr process chang help brand drug manufactur better defend patent
portfolio time
biotech outlook report navig bridg
mani legaci product large-cap biotech begin face patent cliff within next
year increas investor concern base busi franchis maintain off-set
celg revlimid gener entri start full generic potenti greater
entrench earlier entri depend outcom on-going anda litig
biib tecfidera renew concern around dose patent light mylan ipr less-than-expect
patent term extens worsen potenti backstop lack clariti sustain ms franchis life cycl
inci jakafi jakafi inch closer potenti patent expir
mani biolog product face biosimilar entrant though success kept
bay lack approv bpcia litig product sensipar vectibix nplate also face
gener come year
gild hiv franchis taf go gener uncertainti remain around mainten hiv
market domin possibl brand dolutegravir gener f/taf compon use altern
alxn soliri eu soliri face potenti biosimilar entri
regn eylea potenti off-pat
clvss rubraca street disagr valid polymorph patent could place patent expir
disclaim report intend legal advic guarante accur inform purpos
establish attorney-cli relationship
biotech outlook report navig bridg
patent cliff mind believ celg remain best-posit wherea
face signific hurdl
prep biktarvi launch inject hiv
asset nash filgotinib ph iii
advanc novel
gener gilenya
ipr/markman outcom anda litig
part convers strategi
eu oral proceed formul patent
expans eylea dose
indic footprint npdr
advanc ruxolitinib sr formul
combo higher profil asset enter
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
biotech outlook report navig bridg
given still see multipl strategi large-cap biotech implement litig optim
diversifi medium-term
ip regulatori
bpcia anda litig settlement
novel formul less frequent
conveni dose
citizen petit rem
new mode administr
clinic approv hurdl
next-gen product improv efficaci
supplementari ip dose regimen
strateg divestitur diversif
payer agreement reimburs
biotech outlook report navig bridg
new patent offic director continu implement favor chang ipr process
new uspto director announc number procedur chang patent trial
updat claim construct standard broadest reason interpret standard narrow
phillip standard align conserv approach use district court
propos new amend procedur give opportun amend claim proceed
simplifi requir patent elig recent case law develop caus lack clariti
overal chang wont like appli retroact on-going ipr like celg biib
believ longer term yield favor result brand drug manufactur defend
patent gener compani
addit trend favor patent owner could also continu implement come year
pendulum swing back emphasi patent qualiti toward innov protect
congress potenti review patent elig requir would favor provid clear
protect biolog invent
continu strengthen foreign ip strength new trade agreement tariff pressur
new uspto director like continu implement posit chang ptab includ potenti
higher standard review limit serial challeng etc
suprem court still potenti review outstand aspect ipr retroact applic
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
biotech outlook report navig bridg
redefinit address market via person medicin
approach continu enabl biotech rapidli grab
maintain foothold certain nich higher likelihood
minim competit premium price power
area io combin therapi like becom
futur mainstay competit could creat incent consolid
larger compani backbon therapi may seek maintain
leadership incorpor adjac drug technolog
larger compani look establish enhanc posit
therapeut area may look acquir biotech compani
market even novel product class like becom increasingli
competit parp jak cgrp place greater emphasi
minut product differenti biotech
success execut upon launch price potenti pressur
nuanc smaller expect address patient pool slower
perhap previous lofti expect biopharma
expect product
product revisit otezla yescarta kymriah
expect establish flagship product eylea biib ms sma
franchis emerg disrupt agent dupix may see
downward revis competit threat market posit better
crystal becom appreci
player compet group patient
enrol respect clinic trial mm dlbcl patient
car-t bispecif ab product develop
competit coupl favor regulatori environ
maintain trend
gener biosimilar brand
like
take import neg effect innov regulatori permiss one may fulli appreci
medium-term headwind sector likelihood increas competit across mani therapeut area particularli inflamm
oncolog certain neurolog space greater public privat payer empower like leverag control price
presid trump blueprint contain sever initi spur gener biosimilar competit
though uptak slow
biotech outlook report navig bridg
administration/fda explor idea share rem program allow
collect submiss acceler review
potenti chang exclus clock current use
first gener filer delay entranc compet gener
establish uniqu bill payment code biosimilar medicar
part encourag competit biosimilar manufactur
potenti signific impact current develop biosimilar
remicad rituxan avastin herceptin humira
current receiv royalti brand rituxan revenu
significantli erod ex-u biosimilar competit biosimilar rituxan
entri expect
biotech outlook report navig bridg
sever key drug class experienc intensifi brand competit
signific potenti headwind biotech increas competit among recent approv brand drug
amgn aimovig launch exceed expect view two new entrant
quickli gain share ajovi emgal approv space expect
begin aldr eptinezumab iv prophylaxi bhvn rimegep agn
atogep oral prophylaxi migrain
multipl approv competitor percept oncologist littl
differenti among parp free drug program offer parp manufactur
make captur market share difficult biotech limit commerci
multipl emerg competit threat gild establish hiv franchis
includ long-act inject viiv/gsk novel nrtti bnab
sni other though point believ unlik substanti erod
come note increas competit area lymphoma mm
car-t celg bispecif antibodi gsk
manufactur import year competit dynam evolv
summari potenti underappreci disrupt forc across key therapeut class
discuss detail updat report game changer disrupt forc biotech
biotech outlook report navig bridg
companyfranchis riskcompetitorspotenti disrupt achiev risk factorbiibevobrutinib sanofi/principia gener tecfidera generic interv ms scholar myelomagener revlimid inhibitor f/taf generic antibodi truvada inject io cartvrtxcyst fibrosiscftr mrna therapi modul pti gene edit oligo-ab conjug nippon shinyaku dmd gene therapymini-dystrophin gene therapi microdystrophin gene therapi icptpbcfibr novel atogep rapastinel dmd therapymigrain prophylaxiscompanyfranchis riskcompetitorspotenti disrupt achiev risk factor biotech outlook report navig bridg
long-term street estim key product may need revisit light emerg
anticip long-term estim key flagship product see declin street
continu better appreci grow emerg competit larg matur market
spinraza street growth expect like
although previou lofti expect dupix
accur reflect complex epidemiology/dos
expect lead faster-than-expect flatten
well fulli account entranc multipl
competitor like avx roche/ptct
appropri come like room
still downward revis given intensifi
competit novel antibodi target
tslp oral jak inhibitor
street biotech outlook report navig bridg
estim valuat need consid increas competit clinic trial
multipl innov drug discoveri develop coupl permiss regulatori
environ creat potenti bolu upcom approv
competit patient remain challeng especi nich genetically-defin patient subset rare
diseas anticip increas competit patient could
slow trial conduct larg compani resourc and/or examin
orphan drug non-competit diseas area advantag
reduc qualiti outcom due less stringent trial entri criteria requir run non-inferior
head-to-head studi vs first-to-market agent particular drug class
proj number new clinic trial initi year grown past proj increas number ind file fda recent year mean compound put clinic develop biotech outlook report navig bridg
commerci patient
altern mean lower market share opportun diminish price power
believ consensu model alway adequ account effect tend inflat valuat metric
 differ drug reach nsclc market sell
addit use precis therapi diagnost criteria shrink market redefin
address popul influenc patient prognosi cours treatment
exampl lung cancer classifi separ indic base tumor histolog cell origin
genotyp gene express pattern mutat statu
though market get smaller target specif
patient sub-group
increas efficaci patient elig target
achiev high market share patient retent
biotech outlook report navig bridg
earn growth
price-to-earnings multipl lowest year like factor
lower growth worsen margin less diversif vs pharma
could see valuat reset pessim may result
overshot sector discount
one assum compani success deploy capit
 bd improv out-year growth align
broader market larg cap overal would appear attract valu
street estim look low could set-up strong earn
cycl calendar year potenti bottom-lin beat though
still room top-lin miss
long-term ep sale growth expect
larger-cap
biotech market product lowest year perhap
low enough matur franchis pend patent cliff
higher revenu base like much difficult large-cap
garner multipl histor
out-year margin compress complex product
partnership strategi vs could emerg theme
drug price increas less abl serv lever growth
like becom manifest start
base buysid survey result investor see core franchis like
street still neg key product launch space like car-t
vrtx cf product celg revlimid fundament strong
take long-term growth continu key headwind sector compani work grow pipelin contribut larger
revenu base current valuat among mani commercial-stag compani still look like may overli discount dynam
large-cap biotech price-to-earnings multipl remain continu look favor vs
broader market increas attract low valuat could draw generalist
biotech outlook report navig bridg
note large-cap biotech includ celg
biotech outlook report navig bridg
near-term futur ep estim increas revenu project
remain flat
could reflect grow optim around compani maintain disciplin cost structur though
also could result tax reform share buyback artifici inflat earn
 consensu celg
larg cap biotech -- histor ep consensu estim larg cap biotech -- histor cumul sale consensu estim investor view vrtx cf franchis celg revlimid biib spinraza regn dupix
like beat gild yescarta pbyi nerlynx like miss
biotech outlook report navig bridg
yescarta luxturna hcv franchis eylea rubraca soliri spinraza revlimid cf franchis select least like revenu beatsmost like missmost like beataverageleast likelymost like survey investor vs view potenti beat miss key product
biotech outlook report navig bridg
consensu estim obtain factset
productconsensu estimate rbc estimate investor viewrbc viewgild hcv rubraca soliri luxturna revlimid cf expect sale ep growth large-cap biotech low may still room
miss especi long term
see ep revenu growth slightli lag consensu estim onward
biotech outlook report navig bridg
-- us large-cap biotechhistor annual salesstreet estim ep -- us large-cap biotechhistor annual salesstreet estim sale growth -- us large-cap biotechhistor annual salesstreet estim ep growth -- us large-cap biotechhistor annual salesstreet estim estim biotech outlook report navig bridg
long-term margin compress worth watch
see margin improv large-cap number driver make us anticip out-year
margin compress long-term headwind worth watch sector
shift toward complex product like car-t gene therapi higher cog vs
histor small molecul antibodi
exampl like face margin pressur hcv declin continu hiv becom
larger proport base busi shift car-t becom larger compon
higher oper expens associ build-out commerci manufactur infrastructur new
increas use partnership strategi celg royalti could also weigh growth
marginbiibamgngildcelgaverag biotech outlook report navig bridg
influx new manag member across larg cap biotech
re-ignit idea gener busi develop
potenti investor enthusiasm provid fresh perspect
execut chang across large-cap biotech like perpetu
transition/inst could keep investor
percept
sidelin least respect strateg direct becom clearer
preponder execut come larg pharma
diversif ip reimburs challeng face matur
movement execut big pharma large-cap biotech
highlight fact
organ matur
composit earn growth profil like
view valu akin slower-grow less-diversifi
trend toward legaci large-cap pharma biotech execut move
downstream lead emerg privat small-cap compani could
continu attract
influx smaller
compani within space given scientif development
credibl provid
investor interest capit
turnov mid/smid-cap biotech enabl stabil within high-
like continu attract major
sometim consider manag premium place early-
stage non de-risk compani well-regard leadership could
make valuat fragil exagger potenti downsid
compani peer experi setback
take influx new manag member big pharma large-cap biotech could provid fresh perspect foster improv capit
alloc portfolio diversif time though also highlight compani matur could keep investor sidelin
new team gain foot meanwhil mid/smid-cap name high growth opportun may perceiv stable/invest
could risk among smaller-cap compani whose valuat inflat manag premium
four revolv door number manag chang across large-cap biotech mani
execut come big pharma
biotech outlook report navig bridg
old
new
head op jim meyer
presid scott smith
head op anthoni hooper
biotech outlook report navig bridg
one make trend
increas preponder personnel big pharma addit internally-
promot candid reflect matur compani increas need focu
challeng market access competit reimburs share larg pharma co
grow import manag complex organ shepherd bd small
corporate/busi develop effort longer adequ given high revenu base
build need veteran cfo bd leadership
oper commerci increasingli complex navig requir understand
reflect need fresh approach run busi alloc capit given
stagnat valu creation
less turnov smid/small-cap high-growth mid/larg cap compani
high growth opportun and/or rare diseas focu less
crowd domain continu emphas clinic execut
biotech outlook report navig bridg
downstream move legaci exec larger-cap acquir small-cap move
increasingli emerg privat public compani
exampl
leadershipnext endeavorandrew cheng former cmoakeroform zs pharma executivesallakosform kite executivesallogeneform naurex executivesaptinyxscott smith former celg presid coobioatlajeff kindler former chairman ceocentrexiondoug william former head dcodiakform actelion executivesidorsianorbert bischofberg former cmokronospaul friedman former presid ceomadrigaljeremi levin former teva ceoovidform idix executivestransl biogeorg scango former ceovir biotech outlook report navig bridg
experienc leadership provid veteran acumen stewardship though also inflat
recent year seen mani legaci larger-cap acquir small/mid-cap
biotech senior execut move privat emerg compani includ spinoff
version prior compani leverag scientif clinic develop
instil much-need expertis early-stag compani often seen provid
strong valid platform portfolio attract investor interest
time personnel premium could risk substanti rel
extent de-risk asset technolog potenti magnifi downsid
setback someth believ investor mind though
continu presenc well-respect leadership could also help mitig
biotech outlook report navig bridg
need larg biopharma chang narr slow ep
growth pend patent cliff remain high rel favor
cost capit high cash posit enabl
pressur may potenti grow even greater vs
valuat among small/smid-cap compani look
favor albeit could also mean lower willing part
smaller compani acquir
manag commentari vocal desir pursu
deal larger-scal bolt-on acquisit given mani larg
biopharma compani complet restructur and/or new
manag place could increas focu deal
recent resurg deal flow though perhap still
investor expect could begin resurrect
 could draw investor attent away matur core
franchis particularli smid-cap biotech whose valuat
would like benefit increas expect premium
sinc fade earlier enthusiasm
larg biopharma continu leverag cash primarili dividend
share buyback pose question industri overal commit
meaning
larger revenu base like difficult off-set singl smid-
cap deal diminish earn power deal rel
valu paid could also disincentiv least compani
fulli de-risk
industri check indic except gild/kit
may grow predilect toward smaller earlier-stag deal
would transform much longer term structur
partnership structur may mitig risk though like
larg cap compani add pipelin
diversif histor proven less favor smid/mid-
cap co reduc perceiv likelihood ultim acquisit
take believ rel low interest rate strong cash posit pipelin need manag chang catalyz greater
necess thu see environ prime deal-mak
biotech outlook report navig bridg
slow growth major patent cliff biopharma could help drive
mani larg cap compani gener disproportion share overal revenu hand
blockbust drug mani face impend patent cliff come year taf
meantim need make lost sourc revenu stimul growth may encourag futur
larg cap biotech predict show modest ep
cost capit increas
still remain rel cheap
note consensu estim obtain factset
biotech outlook report navig bridg
deploy among large-cap biopharma increas heel tax reform
primarili use buyback dividend
dividend steadili increas among biopharma share repurchas ytd far exceed histor rate
greater
be said biopharma still flush cash biopharma may consid worthwhil use capit
alloc given limit valu gener share buyback
note cash recent report quarter
total valuat among smid-cap look favor year ago pull back
biotech outlook report navig bridg
cap mm cumul biotech market caplarge-cap cap mm averag bucket market capmid-cap biopharma manag commentari bullish late
biotech outlook report navig bridg
companyrec sentiment commentsbiibinvestor hc confer continu work aggress later-stag kind phase commerci opportun challeng obvious opportun fairli price deal later stage tend pricey disciplin run hard space hope get someth done go disciplin got smart llyinvestor hc confer look armo aurka deal done oncolog sigilon diabet product curevac look last nine month pace expect cours capit gener good cash flow busi still cash function tax reform like increas volum term deal bmyinvestor hc confer extrem flexibl respect balanc sheet clearli open look deal regardless absolut expect busi develop strengthen pipelin first prioriti capit want assur constantli scan environ potenti asset rigor analysi everyth possibl obvious done lot deal alreadi year date probabl year-to-d basi probabl one leader industri right billion two big deal lot smaller bd deal expect us continu go continu activ look transact busi think fair say never realli satisfi alway seek faster continu tri activ busi develop team see mani thing come fruition second half year amgninvestor hc confer pretti disciplin come patienc continu think would point look biotech valuat know last sever year look valuat gone place larg premium top smaller publicli trade biotech compani stretch companyrec sentiment certainli shown shi think need find appropri kind asset relat billion billion comment certainli took life far greater would anticip object frame view larg bolt-on like pharmacyclics-lik alway said sever import screen think commit step stone strategi outlin previous past jnjinvestor hc confer go back past coupl year put billion capit work cours actelion amo opportun even consum sector would expect continu path go forward mrkinvestor hc confer high level would say much focus busi develop augment pipelin challeng right asset richli price environ question becom acquir thing reason price creat valu long-termnvspost-avexi acquisit call look ahead continu look opportun valu creat sharehold compani well patient kind bolt-on categori continu assess opportun specif time regard larg transform deal believ need deal drive growth compani would think leadership team unit view far better focus develop pipelin invest pipelin bring product market grow product undertak larg deal biotech outlook report navig bridg
biopharma deal pick total deal valu remain mute
mid-year review number deal full year track inde saw
biopharma acquisit public biotech -- keep par pace
howev actual deal valu fell short project deal valu though
note exclud takeda/shir
overal believ key take-away larg biopharma prefer smaller earlier stage deal privat
compani discount late-stag asset oppos larger acquisit histor seen
space baxalta/shir actelion/jnj pharmacyclics/abbv
higher profil acquisit multipl bidder demand higher premium vs
lower valuat like influenc total transact size
said expect pace deal-mak continu increas pressur biopharma
compani could increas demand drive premium
note exclud takeda-shir deal graph base announc date
number biopharma deal deal valu biopharma deal biotech outlook report navig bridg
seen increas number larg biopharma deal
number announc deal reach
total deal worth complet decemb announc notabl
nv ecyt gsk tesaro await complet
notabl us-bas acquisit includ sanofi acquisit bioverativ januari celgen
acquisit juno januari novarti acquisit avexi april
overal averag deal valu decreas indic pharma pursu lower price target privat compani
note exclud takeda-shir deal acquisit pacbio
public biopharma premiummillionscumul deal valu public biopharma dealstot valueaverag day premium biotech outlook report navig bridg
select biopharma acquisit public biotech
deal highli focus oncolog emerg gene cell therapi platform
expect see addit deal oncolog neurolog potenti nash
date announcedtargetacquirertherapeut areatransact valu llcmerckinfecti corp shirerar pharmagileadcel investor list like takeout candid saw three key acquisit avx juno
tsro
biotech outlook report navig bridg
select like takeout candid investor view loxo like takeout candid
biotech outlook report navig bridg
select like takeout candid generalist prefer specialist prefer loxo favor takeout
candid base investor survey
biotech outlook report navig bridg
candid among
generalist
less favor
perhap due
binari natur jan
investor select like takeout investor select like takeout candid biotech outlook report navig bridg
believ continu scarciti valu increasingli favor
valuat bode well innov late-stag platform-bas
compani seek ipo
anticip fewer ipo due decreas demand follow
especi among earlier stage
record-break year
valuat abil rais capit follow-on offer
heel posit data readout continu favor
increas access privat capit sustain vc-fund privat
biotech continu creat robust pipelin potenti futur
risk dilut due healthi size number
offer though could off-set upsid posit data driven
upward excit new technolog
anticip capit rais temper upsid data catalyst
limit favor valuat time follow-on offer
increas capit need sector remain worth watch long-term
high level privat public invest could limit
level overexuber early-stag modal could increas
risk financ slowdown hiccup
take follow record-break year public privat invest expect slowdown ipo market return
focu later-stag de-risk asset follow mix ipo perform though platform compani continu reson well
overal public privat invest space remain strong bode well continu innov fund new
biotech outlook report navig bridg
ipo market continu reflect increas innov sector
ipo environ improv dramat
evidenc record rais vs
number ipo near peak seen higher
overal valuat good perform indic
continu scarciti valu appetit sector
though like backlog led stronger
 ipo biotech
repres healthcar ipo
comparison ipo financ sector
tech ipo along healthcar
compris ipo activ
note price
total return biotech ipo offer price rel biotech ipo gross proce number rais per ipo biotech ipo perform offer price biotech outlook report navig bridg
expect slight slowdown ipo activ follow histor trend one
still enabl innov later-stag compani capit public equiti market
light robust activ seen expect similar trend prior year prolif year
seem predict futur declin number ipo sector
trend indic favor valuat vs potenti reset number ipo light
uptick number price rang overal number ipo
addit expect earlier-stag modal may challeng time ipo
matur data hand mrna ipo perform indic potenti valuat reset among
compani preclinical/ph asset
note price
price within rang price within rang absolut biotech outlook report navig bridg
increas capit need sector continu fill though area continu
estim number compani less month cash thu like need rais
come year similar level vs
said amount cash burn per quarter entir sector steadili increas
number public compani increas compani progress later stage requir capit
clinic develop
amount rais per follow-on decreas y-o-i
light potenti increas strain public market compani requir access capit
increas cash use continu monitor health capit rais environ given
privat public appetit seem remain high amount rais follow-on far exceed amount
need sector forese major difficulti follow-on market come year
rais follow-on number rais per cash burn cash burn biotech outlook report navig bridg
privat biotech invest appetit remain high light heighten ipo bar
saw record-break year capit invest driven high privat invest coupl
increas number ipo illustr high demand new innov compani
light strong privat public appetit think invest space maintain continu
support ipo pipelin though flurri ipo year expect invest next year stabil
larg number ipo year like quell challeng public investor may histor face
access innov compani public market competit among altern investor
could lead lower number ipo
capit rais total biotech capit investmentiposfollow-onspriv biotech capit investmentiposfollow-onspriv placementvctot capit rais right axi total biotech capit invest capit rais right biotech outlook report navig bridg
continu launch new product class cgrp spinraza
help signifi biotech abil maintain top-lin diversif
organ growth via success invest innov
base busi come
emerg
increas preval new therapeut modal gene
frontier
therapi car-t mrna bring focu next
medicin therefor new attract growth opportun
govern vc fund academ research compani
creation continu sustain
market innov therapi without sacrif risk/benefit
requir maintain high barrier entri
transit develop
increasingli complex therapeut
enabl expans previous untreat diseas thu
gener new market opportun well protect
patent risk maintain higher barrier entri increasingli
number innov remain earli stage develop
yet face test clinic creat long-term invest horizon
 clinic setback remain realiti novel
technolog continu broadli experi could dampen
sentiment invest innov biotech
new modal like gene therapi car-t
approach deliveri reimburs could take system
time adjust get necessari infrastructur place addit tend
lower margin product
transit clinic stage may prove difficult particularli given
challeng manufactur product
therapeut along talent scarciti hurdl creat
futur declin govern spend support research
declin investor appetit support earli stage biotech
fewer blockbust launch number make-or-break clinic
catalyst emerg therapeut area like nash neuropsych
key point could temporarili dampen investor enthusiasm around new
therapeut area neg
take core fundament driver biotech sector d-fuel innov remain intact view multipl
technolog advanc reach clinic invest compani creation continu flow healthi pace
biotech outlook report navig bridg
see continu focu commerci launch sever key product new
on-going launch amgn
on-going launch label
expans nv kymriah
gene therapi
convers rate patient
potenti switch real-
competit oral cgrp
regul amen
price baselin gene-
logist administr
technolog improv
assess durabl
biotech outlook report navig bridg
also anticip seri key clinic catalyst particularli nash neurolog
could reinforc dampen enthusiasm emerg therapeut area
data stellar stellar ph iii
studi selonsertib nash
sage read ph iii data
interim ph iii data icpt regener studi
potenti interim analysi ph iii studi biib
oca nash
aducanumab alzheim
data ph iia studi enta nash
data ph iii studi itci
lumateperon bpd
interim data selonsertib combin
agn ph iii rapastinel data mdd
phase data gnft ph trial
possibl alzheim crenezuamb interim
early-stag novel therapeut modal refin exist class continu emerg
biotech outlook report navig bridg
medicin therapeut
ai-bas discoveri platform improv target optim lead select small
molecul antibodi
complex therapeut antibodi bispecif fc-fusion protein adc
target diseas
on-going improv car-t improv upon efficaci safeti conveni on/off
new therapi begin enter clinic follow setback safeti concern throughout
mani parallel approach aav vector zinc-fing nucleas increas
likelihood could see gene approach becom mainstay form treatment assum
manufactur safeti hurdl overcom
combo precis
year develop number viabl rna-target therapi reach
mrna year-end ipo potenti class may yet fulli recogn
combin i/o chemo target therapi area develop surround
increas excit initi suffer setback inci epacadostat
nktr howev indic implement may simpl initi thought
precis medicin approv loxo astella etc site-agnost label breast
breast etc appear increas traction expand new regulatori approach class
biotech outlook report navig bridg
emerg trend industri on-going shift toward complex therapeut
shift toward complex biolog agent cellular therapi gene therapi
continu fuel innov space result
product higher barrier entri due level know-how complex need manufactur
develop
overal lack tradit patent risk seen small molecul simpler biolog
abil treat previous untreat diseas even cure instanc better address
area unmet need improv upon current treatment paradigm
light chang innov environ see number key hurdl worth watch
scarciti area like gene therapi especi problemat ensur strong oper
excel given high degre complex space
manufactur scalabl challeng transit clinic commerci stage
margin compress discuss earn growth section
biotech outlook report navig bridg
could see catalyst relat number innov plu
data final data shortli
split congress work togeth
oral ph iii data
pti tripl combo data cf
continu launch first gene therapi
emerg presidenti candid
continu negoti china
inci jakafi combo therapi
celg ozanimod nda resubmiss
multipl data readout nash
data
selinexor r/r mm pdufa
ultomiri pnh pdufa
potenti celg settlement drl
oraxol data breast cancer
eylea diabet retinopathi
appoint instal
execut key role
vosoritid readout
pdufa
slow ipo pace
biotech outlook report navig bridg
investor expect key sector catalyst mix
investor view celg reach favor settlement dr reddi icpt regener trial
success posit readout sage studi like occur
investor see gild nash trial meet primari endpoint amgn neulasta sale declin
unlik occur
 selonsertib meet primari endpoint ph iii stellar nash trialsatnx-oraxol demonstr superior vs iv paclitaxel metastat breastcanc trialbiib ipr tecfidera dose patent institutedamgn sensipar gener launch neulasta sale biosimiilar gain formulari access price demonstr proof-of-concept singl agent activ basket trialin mtap-delet tumorsalxn-european patent offic uphold soliriscomposit matter com provid exclus extens ocaliva meet primari endpoint ph iii regener nash interimanalysissgen- enfortumab vedotin drive orr suffici acceleratedapprov muc ph ii trialcelg reach favor settlement dr reddi gener revlimidsag show statist signific benefit ph ii/iii post-partumdepress studyinvestor select least like outcom catalystsleast likelymost likelyaverageleast likelymost like biotech outlook report navig bridg
companydrugeventtimingfprxbemarituzumabpres data trial combin gastric cancer ph iii datajanuarycelgrevlimiddecis drl ipr md mou patentsfebruari pnhfebruari date acut gvhdfebruari ad adolesc sbla march lotu ipr mm mou patentsmarch ppdmarch ivbla ph iii finch studi ph iii finch studi data stellar phase studi finch mtx-ir ra ph iii data trial prolong trial acut pre-term combo dose complet data doublet cf data cf gene therapyfirst data tripl combo ph iii mmpdufa date selinexor penta-refractori mmapril cv risk reduct sbla april hyperlipidemia sbla april hear on-going anda litigationapril regneyleapdufa diabet retinopathi sbla may fact discoveri on-going anda litigationmay pivot ph iii prep data stellar phase studi data ph ii studi cutan lupu data ph ii studi sjogren ph ii studi ebola nunuc data ph ii indicationsdata ph ii studi fistul ph iii studi bipolar interim analysi ph iii file friedrich submiss week interim data nash combo data hematolog malign ph studi addit ph iii regener nash combo egfr nsclc file pomp result part bpd result gallop trial data vs transcend enrol ph iii north trial uc settlement gener anda ph ii nash indicationsdata ph ii studi small-bowel enrol patient secondari efficaci analysi trial nda acceler biotech outlook report navig bridg
companydrugeventtimingitcilumateperon approv nda schizophreniaseptemb data poc ph ii rsv challeng studi ph studi hiv data atla phase studi selonsertib and/or and/or approv commerci launch peanut result atla trial moderate-to-sever result eclips trial data line fl result ph iii uuti cuti data primros trial menstrual bleed associ uterin data part trial result trial mmtop-lin data ph iii boston studi data part trial data ph iii ad ph iib studi cystic mmpotenti full approv dlbclpotenti acceler approv refractori pivot trial ph studi ph ib arm hbv top-lin data trial express cancer undisclos medic indicationsdata ph ii sjogren combo ph studi w/ subcutan acut ph iii studi file full approv ruxolitinibdata ph iii trial ph iii treatment-nav acut gvhd nda submiss ph ii readout bladder cancer w/ continu data fl margin zone mantl cell nv cmet nda submiss alk-cmet amplifi i/ii top-line bladder ca combo w/ atezolizumab gbm combo interim data hpv-associ recurrent/metastat head neck data vulvar anal dysplasia ph ii dlbclsubmit nda pot acceler approv refractori biotech outlook report navig bridg
biotech outlook report navig bridg
